Pages that link to "Q33666543"

The following pages link to Chromatin modifications as therapeutic targets in MLL-rearranged leukemia (Q33666543):

Displaying 34 items.

• SYK is a critical regulator of FLT3 in acute myeloid leukemia (Q24337247) (← links)
• Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? (Q26801573) (← links)
• Targets, models and challenges in osteoarthritis research (Q26850147) (← links)
• Acetylation Reader Proteins: Linking Acetylation Signaling to Genome Maintenance and Cancer (Q28076086) (← links)
• Disordered epigenetic regulation in MLL-related leukemia (Q30422159) (← links)
• NUP98-PHF23 is a chromatin-modifying oncoprotein that causes a wide array of leukemias sensitive to inhibition of PHD histone reader function. (Q33601322) (← links)
• Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens (Q33835065) (← links)
• Metallothionein III (MT3) is a putative tumor suppressor gene that is frequently inactivated in pediatric acute myeloid leukemia by promoter hypermethylation (Q33847875) (← links)
• Genome-wide localization of small molecules (Q34306973) (← links)
• Small-molecular modulators of cancer-associated epigenetic mechanisms (Q34628002) (← links)
• AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. (Q34918857) (← links)
• SWI/SNF Subunits SMARCA4, SMARCD2 and DPF2 Collaborate in MLL-Rearranged Leukaemia Maintenance (Q35842297) (← links)
• Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond (Q35967446) (← links)
• JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors (Q36199628) (← links)
• The histone methyltransferase DOT1L: regulatory functions and a cancer therapy target (Q36250669) (← links)
• Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l (Q36730426) (← links)
• MLL1 and MLL1 fusion proteins have distinct functions in regulating leukemic transcription program (Q36906949) (← links)
• Exploiting the Epigenome to Control Cancer-Promoting Gene-Expression Programs. (Q36956610) (← links)
• Targeted drug discovery for pediatric leukemia (Q36989223) (← links)
• An MLL-dependent network sustains hematopoiesis. (Q37031831) (← links)
• Molecular and Epigenetic Mechanisms of MLL in Human Leukemogenesis (Q38161393) (← links)
• Targeting epigenetic regulators for cancer therapy (Q38191266) (← links)
• Drugging Chromatin in Cancer: Recent Advances and Novel Approaches. (Q38641649) (← links)
• ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. (Q38714672) (← links)
• The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. (Q38830100) (← links)
• Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. (Q41317361) (← links)
• Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in NPM1 Mutant Leukemia. (Q41616680) (← links)
• The lasting influence of LSD1 in the blood (Q41947883) (← links)
• Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells (Q46932033) (← links)
• The dTAG system for immediate and target-specific protein degradation. (Q52340959) (← links)
• Discovery of BET bromodomain inhibitors and their role in target validation (Q54933470) (← links)
• DOT1L inhibition is lethal for multiple myeloma due to perturbation of the endoplasmic reticulum stress pathway (Q90671923) (← links)
• The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development (Q92576196) (← links)
• The miR-5694/AF9/Snail axis provides metastatic advantages and a therapeutic target in basal-like breast cancer (Q102319761) (← links)